

Soni Savai Pullamsetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7391743/publications.pdf>

Version: 2024-02-01

101
papers

6,246
citations

70961

41
h-index

71532

76
g-index

109
all docs

109
docs citations

109
times ranked

7882
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. <i>European Respiratory Journal</i> , 2019, 53, 1801887.	3.1	776
2	Immune and Inflammatory Cell Involvement in the Pathology of Idiopathic Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 186, 897-908.	2.5	296
3	Pro-proliferative and inflammatory signaling converge on FoxO1 transcription factor in pulmonary hypertension. <i>Nature Medicine</i> , 2014, 20, 1289-1300.	15.2	233
4	Inhibition of MicroRNA-17 Improves Lung and Heart Function in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012, 185, 409-419.	2.5	206
5	Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function. <i>Circulation</i> , 2017, 136, 65-79.	1.6	196
6	Macrophage and Cancer Cell Cross-talk via CCR2 and CX3CR1 Is a Fundamental Mechanism Driving Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 437-447.	2.5	186
7	MicroRNA-124 Controls the Proliferative, Migratory, and Inflammatory Phenotype of Pulmonary Vascular Fibroblasts. <i>Circulation Research</i> , 2014, 114, 67-78.	2.0	178
8	Adventitial Fibroblasts Induce a Distinct Proinflammatory/Profibrotic Macrophage Phenotype in Pulmonary Hypertension. <i>Journal of Immunology</i> , 2014, 193, 597-609.	0.4	162
9	Phosphodiesterase 1 Upregulation in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2007, 115, 2331-2339.	1.6	139
10	Combined Tyrosine and Serine/Threonine Kinase Inhibition by Sorafenib Prevents Progression of Experimental Pulmonary Hypertension and Myocardial Remodeling. <i>Circulation</i> , 2008, 118, 2081-2090.	1.6	139
11	Matrix metalloproteinases and their inhibitors in pulmonary hypertension. <i>European Respiratory Journal</i> , 2012, 40, 766-782.	3.1	125
12	Targeting cancer with phosphodiesterase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2010, 19, 117-131.	1.9	123
13	Increased smooth muscle cell expression of caveolin-1 and caveolae contribute to the pathophysiology of idiopathic pulmonary arterial hypertension. <i>FASEB Journal</i> , 2007, 21, 2970-2979.	0.2	121
14	Role of Epidermal Growth Factor Inhibition in Experimental Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010, 181, 158-167.	2.5	118
15	Translational Advances in the Field of Pulmonary Hypertension. From Cancer Biology to New Pulmonary Arterial Hypertension Therapeutics. Targeting Cell Growth and Proliferation Signaling Hubs. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 425-437.	2.5	117
16	Reprogramming of tumor-associated macrophages by targeting β -catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. <i>Science Advances</i> , 2020, 6, eaaz6105.	4.7	110
17	Spatial Density and Distribution of Tumor-Associated Macrophages Predict Survival in Non-Small Cell Lung Carcinoma. <i>Cancer Research</i> , 2020, 80, 4414-4425.	0.4	109
18	Role of Src Tyrosine Kinases in Experimental Pulmonary Hypertension. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 1354-1365.	1.1	108

#	ARTICLE	IF	CITATIONS
19	Heterogeneity in Lung ¹⁸ F FDG Uptake in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2013, 128, 1214-1224.	1.6	107
20	Aberrant expression and activity of histone deacetylases in sporadic idiopathic pulmonary fibrosis. <i>Thorax</i> , 2015, 70, 1022-1032.	2.7	106
21	Hypoxia-inducible factor signaling in pulmonary hypertension. <i>Journal of Clinical Investigation</i> , 2020, 130, 5638-5651.	3.9	104
22	Microenvironmental Th9 and Th17 lymphocytes induce metastatic spreading in lung cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 3560-3575.	3.9	103
23	Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma. <i>PLoS ONE</i> , 2015, 10, e0139073.	1.1	101
24	Notch1 signalling regulates endothelial proliferation and apoptosis in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 48, 1137-1149.	3.1	89
25	Evaluation of Angiogenesis Using Micro-Computed Tomography in a Xenograft Mouse Model of Lung Cancer. <i>Neoplasia</i> , 2009, 11, 48-56.	2.3	87
26	FoxO3 an important player in fibrogenesis and therapeutic target for idiopathic pulmonary fibrosis. <i>EMBO Molecular Medicine</i> , 2018, 10, 276-293.	3.3	85
27	Expression and Activity of Phosphodiesterase Isoforms during Epithelial Mesenchymal Transition: The Role of Phosphodiesterase 4. <i>Molecular Biology of the Cell</i> , 2009, 20, 4751-4765.	0.9	84
28	Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008, 178, 188-196.	2.5	82
29	A RASSF1A-HIF1 α loop drives Warburg effect in cancer and pulmonary hypertension. <i>Nature Communications</i> , 2019, 10, 2130.	5.8	77
30	Novel and Emerging Therapies for Pulmonary Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 394-400.	2.5	75
31	Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	69
32	Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. <i>Nature Communications</i> , 2019, 10, 2204.	5.8	69
33	Targeting histone acetylation in pulmonary hypertension and right ventricular hypertrophy. <i>British Journal of Pharmacology</i> , 2021, 178, 54-71.	2.7	69
34	5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. <i>BioMed Research International</i> , 2015, 2015, 1-8.	0.9	62
35	Identification and Functional Characterization of Hypoxia-Induced Endoplasmic Reticulum Stress Regulating lncRNA (HypERlnc) in Pericytes. <i>Circulation Research</i> , 2017, 121, 368-375.	2.0	61
36	The Role of Dimethylarginine Dimethylaminohydrolase in Idiopathic Pulmonary Fibrosis. <i>Science Translational Medicine</i> , 2011, 03, 87ra53.	5.8	59

#	ARTICLE	IF	CITATIONS
37	Constitutive Reprogramming of Fibroblast Mitochondrial Metabolism in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 55, 47-57.	1.4	59
38	miR-223â€œIGF-IR signalling in hypoxia- and load-induced right-ventricular failure: a novel therapeutic approach. <i>Cardiovascular Research</i> , 2016, 111, 184-193.	1.8	54
39	Therapeutic potential of KLF2-induced exosomal microRNAs in pulmonary hypertension. <i>Nature Communications</i> , 2020, 11, 1185.	5.8	52
40	Classical IL-6 signaling: a promising therapeutic target for pulmonary arterial hypertension. <i>Journal of Clinical Investigation</i> , 2018, 128, 1720-1723.	3.9	46
41	Potential long-term effects of SARS-CoV-2 infection on the pulmonary vasculature: a global perspective. <i>Nature Reviews Cardiology</i> , 2022, 19, 314-331.	6.1	46
42	Long Noncoding RNA TYKRIL Plays a Role in Pulmonary Hypertension via the p53-mediated Regulation of PDGFRÎ². <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 1445-1457.	2.5	45
43	Hypoxic Pulmonary Hypertension in Mice with Constitutively Active Plateletâ€œDerived Growth Factor Receptorâ€œÎ². <i>Pulmonary Circulation</i> , 2011, 1, 259-268.	0.8	44
44	Transcription Factors, Transcriptional Coregulators, and Epigenetic Modulation in the Control of Pulmonary Vascular Cell Phenotype: Therapeutic Implications for Pulmonary Hypertension (2015) Tj ETQq0 0 0 rgB0,6 Overlock 4.0 Tf 50		
45	cAMP Phosphodiesterase Inhibitors Increases Nitric Oxide Production by Modulating Dimethylarginine Dimethylaminohydrolases. <i>Circulation</i> , 2011, 123, 1194-1204.	1.6	42
46	Pulmonary endothelial cell DNA methylation signature in pulmonary arterial hypertension. <i>Oncotarget</i> , 2017, 8, 52995-53016.	0.8	42
47	Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice. <i>BMC Pulmonary Medicine</i> , 2010, 10, 26.	0.8	38
48	Genomic Location of PRMT6-Dependent H3R2 Methylation Is Linked to the Transcriptional Outcome of Associated Genes. <i>Cell Reports</i> , 2018, 24, 3339-3352.	2.9	38
49	Characterization of a murine model of monocrotaline pyrrole-induced acute lung injury. <i>BMC Pulmonary Medicine</i> , 2008, 8, 25.	0.8	36
50	Phosphodiesterase 10A Upregulation Contributes to Pulmonary Vascular Remodeling. <i>PLoS ONE</i> , 2011, 6, e18136.	1.1	36
51	Glycogen Synthase Kinase 3beta Contributes to Proliferation of Arterial Smooth Muscle Cells in Pulmonary Hypertension. <i>PLoS ONE</i> , 2011, 6, e18883.	1.1	36
52	The soluble guanylate cyclase activator HMR1766 reverses hypoxia-induced experimental pulmonary hypertension in mice. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2009, 297, L658-L665.	1.3	35
53	Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling. <i>International Journal of Cardiology</i> , 2013, 167, 2630-2637.	0.8	35
54	Epigenetic mechanisms in pulmonary arterial hypertension: the need for global perspectives. <i>European Respiratory Review</i> , 2016, 25, 135-140.	3.0	35

#	ARTICLE	IF	CITATIONS
55	Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. <i>Respiratory Research</i> , 2007, 8, 4.	1.4	34
56	The role of dimethylarginine dimethylaminohydrolase (<sc>DDAH</sc>) in pulmonary fibrosis. <i>Journal of Pathology</i> , 2013, 229, 242-249.	2.1	34
57	The emerging role of epigenetics in pulmonary hypertension. <i>European Respiratory Journal</i> , 2016, 48, 903-917.	3.1	32
58	Effects of anti-inflammatory vagus nerve stimulation on the cerebral microcirculation in endotoxemic rats. <i>Journal of Neuroinflammation</i> , 2012, 9, 183.	3.1	30
59	A Combination Hybrid-Based Vaccination/Adoptive Cellular Therapy to Prevent Tumor Growth by Involvement of T Cells. <i>Cancer Research</i> , 2007, 67, 5443-5453.	0.4	26
60	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. <i>Thrombosis and Haemostasis</i> , 2006, 95, 720-727.	1.8	26
61	Metabolism in tumour-associated macrophages: a quid pro quo with the tumour microenvironment. <i>European Respiratory Review</i> , 2020, 29, 200134.	3.0	25
62	Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. <i>Scientific Reports</i> , 2020, 10, 12864.	1.6	24
63	Phosphodiesterase 6 subunits are expressed and altered in idiopathic pulmonary fibrosis. <i>Respiratory Research</i> , 2010, 11, 146.	1.4	22
64	PAFAH1B1 and the lncRNA <i>NONHSAT073641</i> maintain an angiogenic phenotype in human endothelial cells. <i>Acta Physiologica</i> , 2016, 218, 13-27.	1.8	22
65	Noncanonical HIPPO/MST Signaling via BUB3 and FOXO Drives Pulmonary Vascular Cell Growth and Survival. <i>Circulation Research</i> , 2022, 130, 760-778.	2.0	19
66	Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction. <i>British Journal of Pharmacology</i> , 2021, 178, 31-53.	2.7	18
67	Epigenetic Mechanisms in Parenchymal Lung Diseases: Bystanders or Therapeutic Targets?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 546.	1.8	16
68	CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension. <i>European Respiratory Journal</i> , 2021, 57, 1901192.	3.1	15
69	Epigenetic reactivation of transcriptional programs orchestrating fetal lung development in human pulmonary hypertension. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	15
70	Epigenetic silencing of downstream genes mediated by tandem orientation in lung cancer. <i>Scientific Reports</i> , 2017, 7, 3896.	1.6	14
71	Restoration of Megalin-Mediated Clearance of Alveolar Protein as a Novel Therapeutic Approach for Acute Lung Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2017, 57, 589-602.	1.4	14
72	Hybrid-Primed Lymphocytes and Hybrid Vaccination Prevent Tumor Growth of Lewis Lung Carcinoma in Mice. <i>Journal of Immunotherapy</i> , 2006, 29, 175-187.	1.2	13

#	ARTICLE	IF	CITATIONS
73	Epigenetic Inactivation of the Tumor Suppressor IRX1 Occurs Frequently in Lung Adenocarcinoma and Its Silencing Is Associated with Impaired Prognosis. <i>Cancers</i> , 2020, 12, 3528.	1.7	13
74	Fibroblast Growth Factor-14 Acts as Tumor Suppressor in Lung Adenocarcinomas. <i>Cells</i> , 2020, 9, 1755.	1.8	12
75	Disrupted PI3K subunit p110 α signaling protects against pulmonary hypertension and reverses established disease in rodents. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	12
76	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican. <i>Cancers</i> , 2021, 13, 208.	1.7	10
77	Tyrosine kinase inhibitors with antiangiogenic properties for the treatment of non-small cell lung cancer. <i>Expert Opinion on Investigational Drugs</i> , 2011, 20, 61-74.	1.9	9
78	Metastasis-Associated Protein 2 Represses NF- κ B to Reduce Lung Tumor Growth and Inflammation. <i>Cancer Research</i> , 2020, 80, 4199-4211.	0.4	9
79	Epigenetic Regulation by Suv4-20h1 in Cardiopulmonary Progenitor Cells Is Required to Prevent Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease. <i>Circulation</i> , 2021, 144, 1042-1058.	1.6	9
80	Hidden Treasures: Macrophage Long Non-Coding RNAs in Lung Cancer Progression. <i>Cancers</i> , 2021, 13, 4127.	1.7	7
81	Effect of nitric oxide synthase (NOS) inhibition on macro- and microcirculation in a model of rat endotoxic shock. <i>Thrombosis and Haemostasis</i> , 2006, 95, 720-7.	1.8	7
82	Noninvasive Surrogate Markers of Pulmonary Hypertension Are Associated with Poor Survival in Patients with Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 1316-1319.	2.5	6
83	Vascular Stiffness and Mechanotransduction: Back in the Limelight. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 527-530.	2.5	5
84	Depletion of Numb and Numlike in Murine Lung Epithelial Cells Ameliorates Bleomycin-Induced Lung Fibrosis by Inhibiting the β -Catenin Signaling Pathway. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 639162.	1.8	5
85	Picturing of the Lung Tumor Cellular Composition by Multispectral Flow Cytometry. <i>Frontiers in Immunology</i> , 2022, 13, 827719.	2.2	5
86	Association of Clonal Hematopoiesis of Indeterminate Potential with Inflammatory Gene Expression in Patients with COPD. <i>Cells</i> , 2022, 11, 2121.	1.8	5
87	Zooming into Cellular and Molecular Heterogeneity of Pulmonary Hypertension. What More Single-Cell Omics Can Offer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 941-943.	2.5	3
88	Exposomes to Exosomes: Exosomes as Tools to Study Epigenetic Adaptive Mechanisms in High-Altitude Humans. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8280.	1.2	3
89	Matrix Metalloproteinase-8 in Pulmonary Hypertension: The Sheep in the Wolf's Skin?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 1361-1363.	2.5	3
90	Inhibition Of MicroRNA-17 Improves Lung And Heart Function In Experimental Pulmonary Hypertension. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
91	EpiHope for the Treatment of Pulmonary Arterial Hypertension: Selective versus Nonselective BET Inhibition. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 1188-1190.	2.5	1
92	A FOX-like Mechanism Regulating Lung Fibroblasts: Are We Getting There?. American Journal of Respiratory Cell and Molecular Biology, 2020, 63, 723-724.	1.4	1
93	Utilising biomarkers to predict right heart maladaptive phenotype: a step toward precision medicine. European Respiratory Journal, 2021, 57, 2004506.	3.1	1
94	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. Global Cardiology Science & Practice, 2020, 2020, e202010.	0.3	1
95	Cancer and pulmonary hypertension: Learning lessons and real-life interplay. Global Cardiology Science & Practice, 2020, 2020, e202010.	0.3	1
96	The Role Of Forkhead Box O 3a (FoxO3a) Transcription Factors In The Pathogenesis Of Pulmonary Fibrosis. , 2012, , .		0
97	Reply to: Pulmonary Hypertension: A Predictor of Lung Cancer Prognosis?. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1113.	2.5	0
98	Role and regulation of Jumonji C domain-containing histone demethylases 1A and 2B in pulmonary hypertension. , 2016, , .		0
99	LSC - 2017 - Reprogramming Of Tumor Associated Macrophages By Modulating Wnt/ÅŸ-catenin Signalling In Lung Cancer. , 2017, , .		0
100	Histone Deacetylase 7 regulates master transcription factors and modulates mitochondrial function. , 2017, , .		0
101	LncRNAs: Emerging Regulators of PDGF Signaling. American Journal of Respiratory Cell and Molecular Biology, 2022, , .	1.4	0